Research Guide
Retatrutide vs Tirzepatide
A technical comparison for the research community. Both compounds target incretin pathways, but Retatrutide adds glucagon receptor agonism — a third lever that shifts the metabolic profile reported in early clinical research.
Receptor pharmacology
Tirzepatide is a dual agonist at the GLP-1 and GIP receptors. Retatrutide (LY3437943) is a triple agonist: GLP-1, GIP, and the glucagon receptor. Adding glucagon receptor activity is what differentiates the two on paper — glucagon signaling increases hepatic energy expenditure and lipolysis, which appears in the literature as more pronounced reductions in body weight and hepatic fat compared to dual agonism alone.
Side by side
| Property | Retatrutide | Tirzepatide |
|---|---|---|
| Developer code | LY3437943 | LY3298176 |
| Receptor targets | GLP-1, GIP, glucagon (triple agonist) | GLP-1, GIP (dual agonist) |
| Mechanism note | Glucagon arm raises energy expenditure and hepatic lipolysis | Incretin-only; relies on appetite and insulin response |
| Half-life (approx.) | ~6 days — weekly dosing in trials | ~5 days — weekly dosing |
| Reported weight change (48-wk Phase 2) | Up to ~24% from baseline at 12 mg | Up to ~22.5% (SURMOUNT-1, 72 wk, 15 mg) |
| Hepatic fat | Marked reductions reported in MASLD cohorts | Reductions reported, smaller magnitude |
| Approval status | Investigational (Phase 3 ongoing) | Approved (Mounjaro / Zepbound) |
| Common adverse signal | GI (nausea, vomiting), dose-titration sensitive | GI (nausea, diarrhea), dose-titration sensitive |
Why the glucagon receptor matters
Glucagon is usually framed as the counter-regulator to insulin, but at the receptor level it also drives hepatic fatty-acid oxidation and increases resting energy expenditure. Co-agonizing glucagon alongside GLP-1 offsets the hyperglycemia risk while keeping the energy-expenditure benefit — this is the design thesis behind Retatrutide and the reason early trials show larger reductions in body weight and liver fat than GLP-1 / GIP dual agonism.
The tradeoff is a narrower therapeutic window: glucagon activity is sensitive to dose and titration, and the long-term safety profile in humans is still being characterized in ongoing Phase 3 work (TRIUMPH program).
Handling notes
Both compounds ship lyophilized and require reconstitution with bacteriostatic water before use. See the peptide reconstitution & storage guide for ratios, refrigeration, and reconstituted shelf life.
Research use only
Information on this page is provided for in-vitro and laboratory research. Not for human or veterinary use, not a medical device, and not a substitute for peer-reviewed literature or clinical guidance.